HLS Therapeutics (TSE:HLS) Hits New 1-Year Low – What’s Next?

HLS Therapeutics Inc. (TSE:HLS)’s stock price hit a new 52-week low on Friday . The company traded as low as C$3.00 and last traded at C$3.51, with a volume of 33000 shares traded. The stock had previously closed at C$3.84.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus reduced their price target on shares of HLS Therapeutics from C$3.75 to C$3.25 in a research note on Tuesday, August 13th.

HLS Therapeutics Trading Down 8.6 %

The business’s 50 day moving average price is C$3.48 and its two-hundred day moving average price is C$3.71. The company has a market capitalization of C$111.58 million, a price-to-earnings ratio of -3.31 and a beta of 1.07. The company has a debt-to-equity ratio of 100.44, a quick ratio of 1.01 and a current ratio of 2.02.

HLS Therapeutics (TSE:HLS) last released its earnings results on Thursday, August 8th. The company reported C($0.25) EPS for the quarter, meeting the consensus estimate of C($0.25). HLS Therapeutics had a negative net margin of 40.90% and a negative return on equity of 24.82%. The business had revenue of C$19.87 million during the quarter, compared to analyst estimates of C$19.25 million. Equities analysts forecast that HLS Therapeutics Inc. will post -0.12 earnings per share for the current fiscal year.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.